Cambridge Cognition (COG) Share Price, News & Analysis

Company Overview

Cambridge Cognition Holdings Plc, a neuroscience technology company, develops and markets near-patient cognitive testing techniques in the United States, United Kingdom, the European Union, and internationally. The company offers CANTAB digital cognitive assessment platform for drug development by enabling pharmaceutical companies to take new therapeutics from preclinical consultancy to pivotal studies and approval, as well as supports sponsors to enhance recruitment, develop safe and effective treatments, and enhance research and development efficiency. It also provides CANTAB Connect Research, a proprietary platform that provides insights into behaviours, underlying brain circuits, and measurement of digital cognitive biomarkers; CANTAB Mobile, a touchscreen assessment of memory, mood, and functional status to detect the earliest signs of clinically relevant memory problems; CANTAB Insight to assess cognitive health; and CANTAB BrainHealth for assessing workplace wellbeing. In addition, the company offers electronic questionnaires and scales, a digital bespoke questionnaire; NeuroVocalix, a voice analysis platform to analyze voice to assess neurological change; cognition kit, a high frequency testing kit to detect changes over time and day-to-day cognition with short regular tests using patients' own devices. Cambridge Cognition Holdings Plc was incorporated in 2012 and is based in Cambridge, the United Kingdom.

Key Stats

• Today's Range: 35 to 36
• 50-Day Range: 34 to 45
• 52-Week Range: 23.90 to 45
• Volume: 56,733 shs
• Average Volume: 31,607 shs
• Market Capitalization: £16.29 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: GBX 56
• Consensus Rating: Buy

Cambridge Cognition Stock Analysis - MarketRank™

Cambridge Cognition scored higher than 32% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Cambridge Cognition has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

Cambridge Cognition has a consensus price target of GBX 56, representing about 60.0% upside from its current price of GBX 35.

Amount of Analyst Coverage

Cambridge Cognition has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Cambridge Cognition is -8.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cambridge Cognition is -8.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cambridge Cognition has a P/B Ratio of 4.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for COG.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cambridge Cognition does not currently pay a dividend.

Dividend Growth

Cambridge Cognition does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: N/A

News Sentiment

Cambridge Cognition has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cambridge Cognition insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.43% of the stock of Cambridge Cognition is held by insiders.

Percentage Held by Institutions

15.89% of the stock of Cambridge Cognition is held by institutions.

Company Calendar

• Last Earnings: 4/13/2026
• Today: 5/08/2026

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Health Information Services
• Sub-Industry: N/A
• Current Symbol: LON:COG
• CIK: N/A
• Web: www.cambridgecognition.com
• Phone: 44 1223 810 700
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Cambridge Cognition: GBX 56
• High Price Target: GBX 56
• Low Price Target: GBX 56
• Potential Upside/Downside: +60.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): GBX (3.90)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 34.00
• P/E Growth: N/A
• Net Income: -£1.58 million
• Net Margins: -17.82%
• Pretax Margin: N/A
• Return on Equity: -62.89%
• Return on Assets: -0.30%

Debt

• Debt-to-Equity Ratio: 28.66
• Current Ratio: 0.40
• Quick Ratio: 0.96

Sales & Book Value

• Annual Sales: £9.40 million
• Price / Sales: 1.73
• Cash Flow: GBX 8.13 per share
• Price / Cash Flow: 4.31
• Book Value: GBX 7.27 per share
• Price / Book: 4.82

Miscellaneous

• Outstanding Shares: 46,555,000
• Free Float: N/A
• Market Cap: £16.29 million
• Optionable: Not Optionable
• Beta: 0.83